Table 1 Basic distribution of clinical characteristics of NSCLC patients in the training and validation groups
Characteristic | Training group (n = 233) | P | Validation group (n = 101) | P | ||
|---|---|---|---|---|---|---|
PD-L1 negative (n = 125) | PD-L1 positive (n = 108) | PD-L1 negative (n = 47) | PD-L1 positive (n = 54) | |||
Age (mean ± SD) (years) | 62.24 ± 9.10 | 61.89 ± 9.18 | 0.504 | 62.49 ± 8.17 | 61.54 ± 8.43 | 0.506 |
Sex | Â | Â | 0.048 | Â | Â | 0.016 |
 Male | 65 (52.00%) | 70 (64.81%) |  | 26 (55.32%) | 42 (77.78%) |  |
 Female | 60 (48.00%) | 38 (35.19%) |  | 21 (44.68%) | 12 (22.22%) |  |
Smoking history | Â | Â | 0.023 | Â | Â | 0.044 |
 Never | 73 (58.40%) | 47 (43.52%) |  | 25 (53.19) | 18 (33.33%) |  |
 Current or ever | 52 (41.60%) | 61 (56.48%) |  | 22 (46.81%) | 36 (66.67%) |  |
Pathological type | Â | Â | 0.051 | Â | Â | 0.165 |
 Adenocarcinoma | 10 (84.00%) | 77 (71.30%) |  | 39 (82.98%) | 37 (68.52%) |  |
 Squamous carcinoma | 16 (12.80%) | 24 (22.22%) |  | 6 (12.76%) | 13 (24.07%) |  |
 Adenosquamous carcinoma | 1 (0.80%) | 5 (4.63%) |  | 1 (2.13%) | 4 (7.41%) |  |
 Large cell carcinoma | 3 (2.40%) | 2 (1.85%) |  | 1 (2.13%) | 0 (0%) |  |
Pathological stage | Â | Â | 0.001 | Â | Â | 0.006 |
 I | 78 (62.40%) | 42 (38.89%) |  | 30 (63.83%) | 17 (31.48) |  |
 II | 16 (12.80%) | 17 (15.74%) |  | 6 (12.77%) | 10 (18.52%) |  |
 III | 22 (17.60%) | 25 (23.15%) |  | 6 (12.77%) | 21 (38.89%) |  |
 IV | 9 (7.20%) | 24 (22.22%) |  | 5 (10.64%) | 6 (11.11%) |  |